# Omecamtiv Mecarbil Post-trial Access Study

> **NCT04464525** · PHASE3 · WITHDRAWN · sponsor: **Cytokinetics**

## Conditions studied

- Chronic Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** Omecamtiv mecarbil

## Key facts

- **NCT ID:** NCT04464525
- **Lead sponsor:** Cytokinetics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12-18
- **Primary completion:** 2026-11-27
- **Final completion:** 2026-11-27
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04464525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04464525, "Omecamtiv Mecarbil Post-trial Access Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04464525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*